Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statistics, 2011CA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• American Cancer SocietyCancer facts and figures, 2013Atlanta, GA, USAAmerican Cancer Society2013 Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdfAccessed March 5, 2014
   Google Scholar
• SetiawanVWMonroeKRWilkensLRKolonelLNPikeMCHendersonBEBreast cancer risk factors defined by estrogen and progesterone receptor status: the Multiethnic Cohort StudyAm J Epidemiol2009169101251125919318616
   PubMed Web of Science ®Google Scholar
• AndersonWFChatterjeeNErshlerWBBrawleyOWEstrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results databaseBreast Cancer Res Treat2002761273612408373
   PubMed Web of Science ®Google Scholar
• BachmanKEArganiPSamuelsYThe PIK3CA gene is mutated with high frequency in human breast cancersCancer Biol Ther20043877277515254419
   PubMed Web of Science ®Google Scholar
• SaalLHHolmKMaurerMPIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinomaCancer Res20056572554255915805248
   PubMed Web of Science ®Google Scholar
• Perez-TenorioGAlkhoriLOlssonBPIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancerClin Cancer Res200713123577358417575221
   PubMed Web of Science ®Google Scholar
• HuangJManningBDThe TSC1-TSC2 complex: a molecular switch-board controlling cell growthBiochem J2008412217919018466115
   PubMed Web of Science ®Google Scholar
• MargaritiNFoxSBBottiniAGeneraliDOvercoming breast cancer drug resistance with mTOR inhibitors. Could it be a myth or a real possibility in the short-term future?Breast Cancer Res Treat2011128359960620945086
   PubMed Web of Science ®Google Scholar
• Villarreal-GarzaCCortesJAndreFmTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directionsAnn Oncol201223102526253522553196
   PubMed Web of Science ®Google Scholar
• MillerTWHennessyBTGonzalez-AnguloAMHyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancerJ Clin Invest201012072406241320530877
   PubMed Web of Science ®Google Scholar
• BeeramMTanQTTekmalRRRussellDMiddletonAdeGraffenriedLAAkt-induced endocrine therapy resistance is reversed by inhibition of mTOR signalingAnn Oncol20071881323132817693645
   PubMed Web of Science ®Google Scholar
• deGraffenriedLAFriedrichsWERussellDHInhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activityClin Cancer Res200410238059806715585641
   PubMed Web of Science ®Google Scholar
• Wyeth/PfizerStudy Evaluating Temsirolimus (CCI-779) In Breast NeoplasmsClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2003 [updated April 13, 2011]. Available from http://clinicaltrials.gov/ct2/show/NCT00062751. NLM identifier: NCT00062751Accessed March 11, 2014
   Google Scholar
• CarpenterJRocheHCamponeMRandomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in post-menopausal women with locally advanced or metastatic breast cancerAbstract 564 presented at the American Society of Clinical Oncology Annual MeetingMay 13–17, 2005Orlando, FL, USA
   Google Scholar
• Wyeth/PfizerStudy Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast CancerClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2004 [updated November 7, 2011]. Available from http://clinicaltrials.gov/ct2/show/NCT00083993?term=NCT00083993&rank=1. NLM identifier: NCT00083993Accessed March 11, 2014
   Google Scholar
• WolffACLazarAABondarenkoIRandomized phase III placebo-controlled trial of letrozole plus oral tmsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancerJ Clin Oncol201331219520223233719
   PubMed Web of Science ®Google Scholar
• BhattacharyyaGNBiswasJSinghJHReversal of tamoxifen resistance (hormone resistance) by addition of sirolimus (mTOR inhibitor) in metastatic breastAbstract 16LBA presented at the 2011 European Multidisciplinary Cancer CongressSeptember 23–27, 2011Stockholm, Sweden
   Google Scholar
• AwadaACardosoFFontaineCThe oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokineticsEur J Cancer2008441849118039566
   PubMed Web of Science ®Google Scholar
• ARCAGY/GINECO GroupTamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic CancerClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 Available from http://clinicaltrials.gov/ct2/show/NCT01298713?term=NCT01298713&rank=1. NLM identifier: NCT01298713Accessed March 11, 2014
   Google Scholar
• BachelotTBourgierCCropetCRandomized Phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO studyJ Clin Oncol201230222718272422565002
   PubMed Web of Science ®Google Scholar
• BaselgaJCamponeMPiccartMEverolimus in postmenopausal hormone receptor-positive advanced breast cancerN Engl J Med2012366652052922149876
   PubMed Web of Science ®Google Scholar
• HortobagyiGNPiccartMRugoHEverolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO 2 Phase III trialAbstract S3-7 presented at the CTRC-AACR San Antonio Breast Cancer SymposiumDecember 6–10, 2011San Antonio, TX, USA
   Google Scholar
• YardleyDANoguchiSPritchardKIEverolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysisAdv Ther2013301087088424158787
   PubMed Web of Science ®Google Scholar
• Novartis PharmaceuticalsEverolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole (BOLERO2)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2009 [updated October 18, 2013]. Available from http://clinicaltrials.gov/ct2/show/NCT00863655?term=NCT00863655&rank=1. NLM identifier: NCT00863655Accessed March 11, 2014
   Google Scholar
• BurrisHGnantMHortobagyiGCharacterization of response to everolimus (EVE) in BOLERO-2: a phase 3 trial of EVE plus exemestane (EXE) in postmenopausal women with HR+, HER2− advanced breast cancerAbstract P2-16-17 presented at the San Antonio Breast Cancer SymposiumDecember 10–14, 2013San Antonio, TX, USA
   Google Scholar
• PritchardKIBurrisHA3rdItoYSafety and efficacy of everolimus with exemestane vs exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2Clin Breast Cancer201313642143224267730
   PubMed Web of Science ®Google Scholar
• CamponeMBachelotTGnantMEffect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 studyEur J Cancer201349122621263223735704
   PubMed Web of Science ®Google Scholar
• BeckJTHortobagyiGNCamponeMEverolimus plus exemestane as first-line therapy in HR+ HER2− advanced breast cancer in BOLERO-2Breast Cancer Res Treat2014144345946724362951
   PubMed Web of Science ®Google Scholar
• BurrisHAIIILebrunFRugoHSHealth-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trialCancer2013119101908191523504821
   PubMed Web of Science ®Google Scholar
• MaassNHarbeckNMundhenkeCEverolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR studyJ Cancer Res Clin Oncol2013139122047205624072232
   PubMed Web of Science ®Google Scholar
• GnantMBaselgaJRugoHSEffect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2J Natl Cancer Inst2013105965466323425564
   PubMedGoogle Scholar
• HadjiPLüftnerDFaschingPA4EVER: Does mTOR inhibition have a major clinical impact on bone health in postmenopausal women with hormone receptor positive (HR+) locally advanced breast cancer treated with everolimus (EVE) in combination with exemestane (EXE)?Abstract P6-06-32 presented at the San Antonio Breast Cancer SymposiumDecember 10–14, 2013San Antonio, TX, USA
   Google Scholar
• Novartis PharmaceuticalsOpen-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2− Metastatic or Locally Advanced Breast Cancer (Bolero-4)ClinicalTrials gov [website on the Internet]Bethesda, MDUS National Library of Medicine2012 [updated February 6, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01698918?term=NCT01698918&rank=1. NLM identifier: NCT01698918Accessed February 6, 2014
   Google Scholar
• GradisharWJBachelotTDSaletanSBOLERO-4: multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER+, HER2− metastatic breast cancerAbstract TPS661 presented at the American Society of Clinical Oncology Annual MeetingMay 31 to June 4, 2013Chicago, IL, USA
   Google Scholar
• Novartis PharmaceuticalsA Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer (BOLERO-6)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2013 [updated February 28, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01783444?term=NCT01783444&rank=1. NLM identifier: NCT01783444Accessed February 28, 2014
   Google Scholar
• EjlertsenBJerusalemGHMHurvitzSABOLERO-6: Phase II study of everolimus plus exemestane versus everolimus or capecitabine monotherapy in HR+, HER2− advanced breast cancerAbstract TPS660 presented at the American Society of Clinical Oncology Annual MeetingMay 31 to June 4, 2013Chicago, IL, USA
   Google Scholar
• TreilleuzIArnedosMCropetCPredictive markers of everolimus efficacy in hormone receptor positive (HR+) metastatic breast cancer (MBC): final results of the TAMRAD trial translational studyAbstract 510 presented at the American Society of Clinical Oncology Annual MeetingMay 31 to June 4, 2013Chicago, IL, USA
   Google Scholar
• HortobagyiGNPiccart-GebhartMJRugoHSCorrelation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: results from BOLERO-2Abstract LBA509 presented at the American Society of Clinical Oncology Annual MeetingMay 31 to June 4, 2013Chicago, IL, USA
   Google Scholar